When was Levicept founded?

Levicept was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Levicept located?

Levicept is headquartered in Sandwich, United Kingdom.

How many employees does Levicept have?

As of Apr 30, 2026, the latest employee count at Levicept is 11.

Is Levicept a funded company?

Levicept is a funded company, having raised a total of $50.9M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 2012.

How much is Levicept worth?

The latest valuation of Levicept is $***** as of Nov 17, 2020.

When was the latest funding round of Levicept?

Levicept's latest funding was a $***** Series B round on Sep 2021, with participation from 4 investors. Its primary sector is Orthopedics. Globally, the Orthopedics sector has seen $700M in funding in 2026 to date.

Where does Levicept rank among its competitors?

Levicept ranks 327th amongst 2790 active competitors, of which 935 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Levicept?

Levicept's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and argenx. Among them, Karyopharm secured the most recent funding round in March, 2026.

Levicept - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the treatment of chronic pain. The biological therapy LEVI-04 p75NTR-Fc for the treatment of chronic pain delivers neurotrophin homeostasis by providing stable binding proteins for the excess neurotrophins present in chronic pain.

Website: levicept.com
Social
Email ID: *****@levicept.com

Key Metrics

Founded Year

2012

Location

Sandwich, United Kingdom

Stage

Series B

Total Funding

$50.9M in 8 rounds

Latest Funding Round

Series B, Sep 2021, $*****

Post Money Valuation

$***** as on Nov 17, 2020

Investors

Index Ventures & 9 more

Ranked

327^th among 2790 active competitors

Employee Count

11 as on Apr 30, 2026

Similar Companies

Heron Therapeutics & 378 more

View Levicept's full profile

Levicept is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Levicept Limited CIN: 8190142 , Germany, Active	Aug 22, 2012	-	9 (As on Sep 30, 2023)
Levicept Ltd CIN: 8190142 , United Kingdom, Active	Aug 22, 2012	-	7 (As on Sep 30, 2022)

Levicept has raised a total funding of $50.9M over 8 rounds. Its first funding round was on Mar 2012. Its latest funding round was a Series B round on Sep 2021 for $*****. 4 investors participated in its latest round. Levicept has 9 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Levicept:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 2021	5170796	Series B	6824289	4849335	1444170	1648073
Nov 17, 2020	1402894	Series B	5538380	8744189	8525438	3506481
Sep 14, 2016	7175783	Series A	6362132	4999703	1555913	7353877

Access funding benchmarks and valuations. Sign up today!

View details of Levicept's funding rounds and investors

The founders of Levicept is Simon Westbrook. Eliot Forster is the CEO of Levicept.

Here are the details of Levicept's key team members:

Simon Westbrook: CSO and Founder of Levicept. They serve on the board of 1 company.
Eliot Forster: CEO of Levicept.

Levicept's Board of Directors

Levicept's board has 7 active members. Simon Westbrook, Kevin Stuart Johnson and Eliot Richard Forster are part of team and Francesco Rubertis, Arthur Franken, Md Paul Peter Tak and Rajesh Bhikhu Parekh are independent board members.

Here is the list of Levicept's board of directors:

Name	Type	Representing	Status	Duration
Simon Westbrook	Team	-	Current	13y 8m
jvqlxna	Team	-	Current	8y 3m
Kevin Stuart Johnson	Investor	-	Current	13y 8m
Francesco Rubertis	Independent board member	-	Current	5y 5m
ryordyu	Independent board member	-	Current	6y 9m
ccssu{d	Independent board member	-	Current	7y 1m
{teylqc	Independent board member	-	Current	3y 8m
nswzbvk	Independent board member	-	Past	4y 8m
hyqrveg	Independent board member	-	Past	9y 5m

View details of Levicept's Founder profiles and Board Members

Levicept's employee count trend

Levicept has 11 employees as of Apr 26. Here is Levicept's employee count trend over the years:

Uncover Levicept's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Levicept include Jazz Pharmaceuticals, Sana Biotechnology and argenx. Here is the list of Top 10 competitors of Levicept, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
327th	Levicept 2012, Sandwich (United Kingdom), Series B	Developer of therapeutics for the treatment of chronic pain	$50.9M	Index Ventures, Advent Life Sciences & 8 others	55/100